Clinical trials: Male
Renal Cell Carcinoma
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated…
- Trial name
- CheckMate 374 (NCT02596035)
- Testing
- Nivolumab
- Where
- 39 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Healthy Adult Males
A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects
- Trial name
- NCT05396235
- Testing
- MT-3921
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Renal Insufficiency, Chronic
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
The purpose of this study is to compare how PF-00734200 is adsorbed, distributed, broken down and eliminated by subjects with mild, moderate and severe kidney impairment, by subjects receiving chronic hemodialysis, and by…
- Trial name
- NCT00596518
- Testing
- PF-00734200
- Where
- 4 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Primary Hyperoxaluria Type 1 (PH1)
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
- Trial name
- ILLUMINATE-A (NCT03681184)
- Testing
- Lumasiran
- Where
- 17 sites in United States, France and 6 more
- Volunteers
- 39 people
- Sponsor
- Alnylam Pharmaceuticals
Type II Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to assess the efficacy of ASP1941 based on the changes in HbA1C as well as its safety in Asian subjects with type 2 diabetes mellitus.
- Trial name
- NCT01514838
- Testing
- ASP1941, acarbose
- Where
- 15 sites in South Korea, Taiwan
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Inc
Healthy Subjects
Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects
The primary purpose of this phase 1 study is to investigate the absolute bio-availability of a single oral dose of selexipag, i.e., to assess the amount of selexipag which reaches the blood when administered as an oral tablet…
- Trial name
- NCT02882425
- Testing
- Selexipag for intravenous use, Selexipag for oral use
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Actelion
Renal Impairment
Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects
To investigate the pharmacokinetics of BAY1101042 in subjects with mild to severe renal impairment, stratified according to estimated glomerular filtration rate (eGFR) determined 2-10 days prior to dosing, and age-, weight- and…
- Trial name
- NCT03235076
- Testing
- BAY1101042
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects
The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.
- Trial name
- NCT03110276
- Testing
- EYP001a
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Hypertension, Renal
RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
This is a prospective, multi-center, non-randomized, feasibility study to assess the safety and effectiveness of renal artery sympathetic denervation using the investigational devices in subjects with resistant hypertension.
- Trial name
- RENABLATE-II (NCT02095691)
- Testing
- Celsius® ThermoCool® Renal Denervation
- Volunteers
- 19 people
- Sponsor
- Biosense Webster, Inc.
Healthy
Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects
Effect of food on the pharmacokinetics of BI 1060469 (formulation tablet) in healthy male subjects as well as to investigate pharmacokinetics, safety and tolerability
- Trial name
- NCT02225626
- Testing
- BI 1060469, Other: standard breakfast
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers
This is an open-label, single dose, mass balance and biotransformation study conducted at 1 study center in China. This study will evaluate the absorption, distribution, metabolism, and elimination (ADME), mass balance, safety…
- Trial name
- NCT05716126
- Testing
- [14C]Iruplinalkib (WX-0593)
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Hypothalamic Obesity
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
- Trial name
- NCT04725240
- Testing
- Setmelanotide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Prostate Cancer
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
This is a single arm, open label study of up to 20 patients with prostate cancer scheduled for prostatectomy at the NIH Clinical Center.
- Trial name
- NCT01279785
- Testing
- 123I-MIP-1072
- Where
- United States
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects
To investigate safety, tolerability and pharmacokinetics, and pharmacodynamics of BI 14332 CL
- Trial name
- NCT02211989
- Testing
- BI 14332 CL
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
NSCLC, SCLC
Study of Oral MRT-2359 in Selected Cancer Patients
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer…
- Conditions
- NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL
- Trial name
- NCT05546268
- Testing
- Oral MRT-2359
- Where
- 17 sites in United States
- Volunteers
- 174 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Healthy Subjects
The Mass Balance Study of [14C]JT001
This study is a single center, single dose, non-randomized, open design clinical study.By quantitative analysis of the biological samples of subjects after oral administration of [14C]JT001, the data of human radioactive…
- Trial name
- NCT05802810
- Testing
- [14C]JT001
- Where
- China
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.